GlassScriptPhysician profile
Brian W Wells
NPI 1457666406
$3,619.68
in general payments reported to CMS, 2019-2025
24 companies · $904 in 2025
The $904 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $191 · 2021: $658 · 2022: $530 · 2023: $319 · 2024: $537 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.78 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $825.02 | 2019-2025 | |
| Novo Nordisk INC | $735.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $636.19 | 2019-2025 | |
| Dexcom, INC. | $246.60 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $200.27 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Amgen INC. | $199.49 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $155.74 | 2019-2022 | |
| Abbvie INC. | $146.75 | 2021-2024 | Vraylar, Ubrelvy |
| Insmed, INC. | $116.25 | 2024-2025 | Brinsupri, Arikayce |
| Abbott Laboratories | $40.74 | 2024 | Freestyle Libre 3 |
| La Jolla Pharmaceutical Company | $37.30 | 2024-2025 | Xacduro, Zevtera |
| Astellas Pharma US INC | $33.45 | 2019-2020 | |
| Mylan Specialty L.P. | $31.84 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $30.55 | 2025 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $26.38 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $25.88 | 2023 | |
| Boston Scientific Corporation | $21.93 | 2025 | General - Pain Management |
| Otsuka America Pharmaceutical, INC. | $20.87 | 2021 | |
| Circassia INC. | $19.98 | 2019 | |
| Exact Sciences Corporation | $17.98 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2025 | Relistor |
| Gilead Sciences, INC. | $13.06 | 2021 | |
| Allergan, INC. | $12.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.